Phillip L R Nicolson
Overview
Explore the profile of Phillip L R Nicolson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hassan E, Sutton D, Buka R, Lowe G, Nandra T, Jacob N, et al.
Thromb Res
. 2025 Jan;
247:109258.
PMID: 39827813
Background: Heavy menstrual bleeding (HMB) is a significant clinical burden for premenopausal individuals treated with anticoagulation for acute venous thromboembolism (VTE). Despite its prevalence, HMB management remains poorly studied, with...
2.
Sherratt-Mayhew S, Nicolson P
EJHaem
. 2024 Aug;
5(4):825-828.
PMID: 39157612
Pure red cell aplasia (PRCA) is characterised by normocytic normochromic anaemia, reticulocytopenia and reduced erythroid precursors in bone marrow. PRCA as an immune-related adverse event secondary to immune checkpoint inhibitor...
3.
Smith C, Campos J, Brown H, Jooss N, Ivanova V, Harbi M, et al.
Blood Adv
. 2024 Jul;
8(21):5557-5570.
PMID: 38968150
Platelet C-type lectin-like receptor 2 (CLEC-2) is a hem-immunoreceptor tyrosine-based activation motif-containing receptor that has a critical role in venous thrombosis but minimal involvement in hemostasis. CLEC-2 can be blocked...
4.
Gardner J, Abrams S, Toh C, Parker A, Lovatt C, Nicolson P, et al.
NPJ Vaccines
. 2024 Jun;
9(1):99.
PMID: 38839821
Vaccination has proven to be a valuable tool to combat SARS-CoV-2. However, reports of rare adverse reactions such as thrombosis/thrombocytopenia syndrome after ChAdOx1 nCoV-19 vaccination have caused scientific, public and...
5.
Cooper N, Scully M, Percy C, Nicolson P, Lowe G, Bagot C, et al.
Br J Haematol
. 2024 Mar;
204(6):2442-2452.
PMID: 38429869
Few studies have reported the real-world use of both romiplostim and eltrombopag in immune thrombocytopenia (ITP). TRAIT was a retrospective observational study aimed to evaluate the platelet responses and adverse...
6.
Abrams S, Du M, Shaw R, Johnson C, McGuinness D, Schofield J, et al.
J Thromb Haemost
. 2023 Dec;
22(4):1145-1153.
PMID: 38103733
Background: Adenoviral vector-based COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) is rare but carries significant risks of mortality and long-term morbidity. The underlying pathophysiology of severe disease is still not fully...
7.
Buka R, Montague S, Moran L, Martin E, Slater A, Watson S, et al.
Blood
. 2023 Oct;
143(1):64-69.
PMID: 37883794
Platelet factor 4 (PF4) is an abundant chemokine that is released from platelet α-granules on activation. PF4 is central to the pathophysiology of vaccine-induced immune thrombocytopenia and thrombosis (VITT) in...
8.
Alenazy F, Harbi M, Kavanagh D, Price J, Brady P, Hargreaves O, et al.
J Thromb Haemost
. 2023 Aug;
21(11):3236-3251.
PMID: 37541591
Background: Aspirin and platelet P2Y inhibitors, such as ticagrelor, suboptimally inhibit microvascular thrombosis during ST-elevation myocardial infarction. Glycoprotein (GP) IIb/IIIa inhibitors may further inhibit this but cause excessive bleeding. Objectives:...
9.
Glancy P, Sutton D, Gomez K, Nicolson P, Buka R
EJHaem
. 2023 Feb;
4(1):298-300.
PMID: 36819179
No abstract available.
10.
Smith C, Harbi M, Garcia-Quintanilla L, Rookes K, Brown H, Poulter N, et al.
J Thromb Haemost
. 2022 Oct;
20(12):2939-2952.
PMID: 36239466
Background: New antithrombotic therapies with less effect on bleeding are needed for coronary artery disease. The Btk inhibitor ibrutinib blocks atherosclerotic plaque-mediated thrombus formation. However, it is associated with increased...